These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35656701)

  • 21. Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease.
    Zhang S; Gillihan R; He N; Fields T; Liu S; Green T; Stubbs JR
    Kidney Int; 2013 Oct; 84(4):713-21. PubMed ID: 23698235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conditional Deletion of Murine Fgf23: Interruption of the Normal Skeletal Responses to Phosphate Challenge and Rescue of Genetic Hypophosphatemia.
    Clinkenbeard EL; Cass TA; Ni P; Hum JM; Bellido T; Allen MR; White KE
    J Bone Miner Res; 2016 Jun; 31(6):1247-57. PubMed ID: 26792657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations Between Intravenous Iron, Inflammation and FGF23 in Non-Dialysis Patients with Chronic Kidney Disease Stages 3-5.
    Muras-Szwedziak K; Nowicki M
    Kidney Blood Press Res; 2018; 43(1):143-151. PubMed ID: 29444509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intact FGF23 and α-Klotho during acute inflammation/sepsis in CKD patients.
    Dounousi E; Torino C; Pizzini P; Cutrupi S; Panuccio V; D'Arrigo G; Abd ElHafeez S; Tripepi G; Mallamaci F; Zoccali C
    Eur J Clin Invest; 2016 Mar; 46(3):234-41. PubMed ID: 26728476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations between anemia and FGF23 in the CKiD study.
    Thomas E; Klomhaus AM; Laster ML; Furth SL; Warady BA; Salusky IB; Hanudel MR
    Pediatr Nephrol; 2024 Mar; 39(3):837-847. PubMed ID: 37752381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of Action and Clinical Attributes of Auryxia
    Ganz T; Bino A; Salusky IB
    Drugs; 2019 Jun; 79(9):957-968. PubMed ID: 31134521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Route of intestinal absorption and tissue distribution of iron contained in the novel phosphate binder ferric citrate.
    Vaziri ND; Nunes ACF; Said H; Khazaeli M; Liu H; Zhao Y; Jing W; Cogburn K; Alikhani L; Lau WL
    Nephrol Dial Transplant; 2020 Jul; 35(7):1136-1144. PubMed ID: 32514572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
    Wolf M; Koch TA; Bregman DB
    J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibroblast growth factor 23 is pumping iron: C-terminal-fibroblast growth factor 23 cleaved peptide and its function in iron metabolism.
    Courbon G; David V
    Curr Opin Nephrol Hypertens; 2024 Jul; 33(4):368-374. PubMed ID: 38661434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Phosphate metabolism and iron deficiency].
    Yokoyama K
    Clin Calcium; 2016 Feb; 26(2):241-9. PubMed ID: 26813504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.
    Courbon G; Martinez-Calle M; David V
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):359-366. PubMed ID: 32452919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral iron supplementation with sodium ferrous citrate reduces the serum intact and c-terminal fibroblast growth factor 23 levels of maintenance haemodialysis patients.
    Yamashita K; Mizuiri S; Nishizawa Y; Kenichiro S; Doi S; Masaki T
    Nephrology (Carlton); 2017 Dec; 22(12):947-953. PubMed ID: 27558654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.
    Block GA; Block MS; Smits G; Mehta R; Isakova T; Wolf M; Chertow GM
    J Am Soc Nephrol; 2019 Aug; 30(8):1495-1504. PubMed ID: 31278194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphate Binder, Ferric Citrate, Attenuates Anemia, Renal Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in 5/6 Nephrectomized CKD Rats.
    Jing W; Nunes ACF; Farzaneh T; Khazaeli M; Lau WL; Vaziri ND
    J Pharmacol Exp Ther; 2018 Oct; 367(1):129-137. PubMed ID: 30093458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-renal-Related Mechanisms of FGF23 Pathophysiology.
    Hanudel MR; Laster M; Salusky IB
    Curr Osteoporos Rep; 2018 Dec; 16(6):724-729. PubMed ID: 30353318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.
    Prats M; Font R; García C; Cabré C; Jariod M; Vea AM
    BMC Nephrol; 2013 Jul; 14():167. PubMed ID: 23902731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.
    Edmonston D; Wolf M
    Nat Rev Nephrol; 2020 Jan; 16(1):7-19. PubMed ID: 31519999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure.
    van Breda F; Emans ME; van der Putten K; Braam B; van Ittersum FJ; Kraaijenhagen RJ; de Borst MH; Vervloet M; Gaillard CA
    PLoS One; 2015; 10(6):e0128994. PubMed ID: 26079688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
    Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
    Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibroblast growth factor 23 is upregulated in the kidney in a chronic kidney disease rat model.
    Sugiura H; Matsushita A; Futaya M; Teraoka A; Akiyama KI; Usui N; Nagano N; Nitta K; Tsuchiya K
    PLoS One; 2018; 13(3):e0191706. PubMed ID: 29518087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.